Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression
portes grátis
Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression
Ganai, Shabir Ahmad
Taylor & Francis Ltd
03/2023
154
Dura
Inglês
9781032279862
15 a 20 dias
Descrição não disponível.
1. Abridgement of Classical Histone Deacetylases, Their Inhibitors and Jeopardy of Synthetic Histone Deacetylase Inhibitors
Glimpse of HATs and HDACs
Family of Classical HDACs
Concise explanation of HDACi and their diverse groups
Disquietude of synthetic HDACi
2. Punctilious Overview of Stratification of Natural Histone Deacetylase Inhibitors and Their Different Provenances
2.1 Thorough Classification of Natural HDAC Inhibitors
2.2 Sources of Natural HDAC Inhibitors
2.2.1 Source of Cyclic tetrapeptide HDACi
2.2.2 Natural Hydroxamate HDACi source
2.2.3 Origin of Depsipeptide HDACi
2.2.4 Flavonoid HDACi and Their Natural Sources
2.2.5 Important sources of isothiocyanate group of HDACi
2.2.6 Main Sources of Organosulfur HDACi
2.2.7 Original Sources of Short Chain Fatty acid HDACi
2.2.8. Stilbenes and Their premier sources
2.2.9 Core sources of polyketide
2.2.10 Best sources of HDACi belonging to Bromo-tyrosine derivatives
2.2.11 Natural Origin of Coumarin Derivatives, Prenylated Isoflavones and other HDACi
3. Natural Cyclic Tetrapeptide Histone Deacetylase Inhibitors and Their Optimistic Role in Anticancer Therapy
3.1 Anticancer effect of Chlamydocin
3.2 Promising anticancer property of Apicidin
4. Anticancer Potential of Natural Hydroxamates and Depsipeptides Against Different Disease Models
4.1 Hydroxamate HDACi and their antineoplastic effect
4.2 Anticancer Property of Natural Depsipeptide HDACi
5. Promising Therapeutic Benefits of Flavonoid Histone Deacetylase Inhibitors with Special Emphasis on Modulation of Central Molecular Mechanisms
5.1 Short Introduction to Plant Derived HDAC Inhibitors
5.2 Classification of Phenolic Compounds and Flavonoids
5.3 Extensive Compendium of Flavonoid HDAC Inhibitors
5.4 Antineoplastic Effect of Isoflavonoid HDAC Inhibitors
5.5 Flavanones in obstructing cancer progression
5.6. Antineoplastic property of flavonols
5.6.1 Anticancer potential of Quercetin
5.6.2 Antineoplastic activity of Kaempferol
5.6.3 Antineoplastic characteristics of flavonol Isorhamnetin
5.6.4 Myricetin and fisetin as anticancer flavonols
5.7 Anti-tumour activity of Flavones
5.7.1 Apigenin based anticancer therapy
5.7.2 Chrysin as propitious molecule for belligerent cancers
5.7.3 Sanguine antineoplastic effects of Luteolin
5.7.4 Rutin as anticancer flavone
5.8 Flavanols and their role in cancer therapy
5.9 Anticancer characteristics of chalcones
5.9.1 Ovalitenin A and its role in hampering cancer
5.9.2 Licochalcone A as anticancer chalcone
5.9.3 Panduratin A and its anticancer benefits
5.9.4 Cardamonin as promising antineoplastic natural chalcone
5.9.5 Lonchocarpin and glimpse of its anti-tumour potential
5.10. Anthocyanins as anticancer flavonoids
6. Non-Flavonoid Histone Deacetylase Inhibitors from Natural Sources and Their Stupendous Anticancer Properties
6.1 Promising anticancer effect of isothiocyanates
6.2 Prodigious cytotoxic effect of bromotyrosine HDAC inhibitors
6.3 Cytotoxic effects of organosulfur compounds
6.4 Anticancer characteristics of natural short chain fatty acids
6.5 Antiproliferative effects of stilbenes
6.5.1 Resveratrol as antiproliferative stilbene
6.5.2 Piceatannol in abrogating cancer advancement
6.6 Coumarins in anticancer therapy
7. Flavonoid Inhibitors of Histone Deacetylases in Concert with Conventional Chemotherapeutic Agents for Phenomenal Therapy Against Cancer
7.1 Flavones in association with standard agents
7.1.1 Chrysin in cooperation with standard chemotherapeutics
7.1.2 Luteolin-conventional drugs combination
7.1.3 Apigenin in collaboration with standard cancer therapeutics
7.1.4 Rutin in combinatorial therapy
7.2 Isoflavones and conventional drugs combination
7.2.1 Standard drugs in combination with genistein
7.2.2 Conventional drugs and daidzein association
7.3 Flavanones in doublet therapy with conventional therapeutic molecules
7.3.1 Naringenin augments anticancer effect of usual anticancer drugs
7.3.2 Naringin reinforces effect of conventional antineoplastic agents
7.3.3 Hesperidin and hesperetin in concert with customary therapeutics
7.4 Flavonols in combinational therapy
7.4.1. Isorhamnetin as co-therapheutic with endorsed therapeutics
7.4.2 Quercetin and standard chemotherapeutics in concert
7.4.3 Combining conventional drug molecules with kaempferol
7.4.4 Fisetin-conventional drug combination
7.4.5 Standard drug molecules along with myricetin
7.5 Flavanols in cooperation with standard cancer therapeutics
7.6 Combining conventional compounds with anthocyanins
8. Standard Drugs in Cooperation with Natural Non-Flavonoid Histone Deacetylase Inhibitors for Stunning Therapy Against Belligerent Malignancies
8.1 Combinatorial therapeutic approach involving organosulfurs
8.2 Stilbenes as adjuvant therapeutics with conventional antineoplastic agents
8.2.1 Resveratrol-conventional drug combination
8.2.2 Piceatannol together with certain conventional drugs
8.3 Conventional drugs in union with short chain fatty acids
8.4 Coumarins as adjuvants for standard antineoplastic agents
9. Enhancing Bioactivity and Bioavailability of Natural Histone Deacetylase Inhibitors Through Innovative Nanotechnological Approach
9.1 Nanoparticles containing single natural HDAC inhibitor
9.1.1 Nanoparticles loaded with Quercetin
9.1.2 Luteolin loaded nanovectors in cancer monotherapy
9.1.3 Resveratrol nanoparticles in singlet cancer therapy
9.1.4 Nanoparticles loaded with Chrysin for cancer treatment
9.1. 5 Nano-apigenin in cancer therapy
9.1.6 Anticancer monotherapy with rutin-nanoparticles
9.1.7 Piceatannol nanoparticles in singlet cancer therapy
9.1.8 Nano-encapsulated sulforaphane for therapy against cancer
9.2 Nanocombinatorial anticancer therapy with herbal HDACi
9.2.1. Quercetin in nano-combinational therapy
9.2.2 Luteolin-other molecules dual encapsulation
9.2.3 Resveratrol and standard drug co-encapsulation
9.3 Shortcomings of nanoparticles integrated with HDAC inhibitors
Glimpse of HATs and HDACs
Family of Classical HDACs
Concise explanation of HDACi and their diverse groups
Disquietude of synthetic HDACi
2. Punctilious Overview of Stratification of Natural Histone Deacetylase Inhibitors and Their Different Provenances
2.1 Thorough Classification of Natural HDAC Inhibitors
2.2 Sources of Natural HDAC Inhibitors
2.2.1 Source of Cyclic tetrapeptide HDACi
2.2.2 Natural Hydroxamate HDACi source
2.2.3 Origin of Depsipeptide HDACi
2.2.4 Flavonoid HDACi and Their Natural Sources
2.2.5 Important sources of isothiocyanate group of HDACi
2.2.6 Main Sources of Organosulfur HDACi
2.2.7 Original Sources of Short Chain Fatty acid HDACi
2.2.8. Stilbenes and Their premier sources
2.2.9 Core sources of polyketide
2.2.10 Best sources of HDACi belonging to Bromo-tyrosine derivatives
2.2.11 Natural Origin of Coumarin Derivatives, Prenylated Isoflavones and other HDACi
3. Natural Cyclic Tetrapeptide Histone Deacetylase Inhibitors and Their Optimistic Role in Anticancer Therapy
3.1 Anticancer effect of Chlamydocin
3.2 Promising anticancer property of Apicidin
4. Anticancer Potential of Natural Hydroxamates and Depsipeptides Against Different Disease Models
4.1 Hydroxamate HDACi and their antineoplastic effect
4.2 Anticancer Property of Natural Depsipeptide HDACi
5. Promising Therapeutic Benefits of Flavonoid Histone Deacetylase Inhibitors with Special Emphasis on Modulation of Central Molecular Mechanisms
5.1 Short Introduction to Plant Derived HDAC Inhibitors
5.2 Classification of Phenolic Compounds and Flavonoids
5.3 Extensive Compendium of Flavonoid HDAC Inhibitors
5.4 Antineoplastic Effect of Isoflavonoid HDAC Inhibitors
5.5 Flavanones in obstructing cancer progression
5.6. Antineoplastic property of flavonols
5.6.1 Anticancer potential of Quercetin
5.6.2 Antineoplastic activity of Kaempferol
5.6.3 Antineoplastic characteristics of flavonol Isorhamnetin
5.6.4 Myricetin and fisetin as anticancer flavonols
5.7 Anti-tumour activity of Flavones
5.7.1 Apigenin based anticancer therapy
5.7.2 Chrysin as propitious molecule for belligerent cancers
5.7.3 Sanguine antineoplastic effects of Luteolin
5.7.4 Rutin as anticancer flavone
5.8 Flavanols and their role in cancer therapy
5.9 Anticancer characteristics of chalcones
5.9.1 Ovalitenin A and its role in hampering cancer
5.9.2 Licochalcone A as anticancer chalcone
5.9.3 Panduratin A and its anticancer benefits
5.9.4 Cardamonin as promising antineoplastic natural chalcone
5.9.5 Lonchocarpin and glimpse of its anti-tumour potential
5.10. Anthocyanins as anticancer flavonoids
6. Non-Flavonoid Histone Deacetylase Inhibitors from Natural Sources and Their Stupendous Anticancer Properties
6.1 Promising anticancer effect of isothiocyanates
6.2 Prodigious cytotoxic effect of bromotyrosine HDAC inhibitors
6.3 Cytotoxic effects of organosulfur compounds
6.4 Anticancer characteristics of natural short chain fatty acids
6.5 Antiproliferative effects of stilbenes
6.5.1 Resveratrol as antiproliferative stilbene
6.5.2 Piceatannol in abrogating cancer advancement
6.6 Coumarins in anticancer therapy
7. Flavonoid Inhibitors of Histone Deacetylases in Concert with Conventional Chemotherapeutic Agents for Phenomenal Therapy Against Cancer
7.1 Flavones in association with standard agents
7.1.1 Chrysin in cooperation with standard chemotherapeutics
7.1.2 Luteolin-conventional drugs combination
7.1.3 Apigenin in collaboration with standard cancer therapeutics
7.1.4 Rutin in combinatorial therapy
7.2 Isoflavones and conventional drugs combination
7.2.1 Standard drugs in combination with genistein
7.2.2 Conventional drugs and daidzein association
7.3 Flavanones in doublet therapy with conventional therapeutic molecules
7.3.1 Naringenin augments anticancer effect of usual anticancer drugs
7.3.2 Naringin reinforces effect of conventional antineoplastic agents
7.3.3 Hesperidin and hesperetin in concert with customary therapeutics
7.4 Flavonols in combinational therapy
7.4.1. Isorhamnetin as co-therapheutic with endorsed therapeutics
7.4.2 Quercetin and standard chemotherapeutics in concert
7.4.3 Combining conventional drug molecules with kaempferol
7.4.4 Fisetin-conventional drug combination
7.4.5 Standard drug molecules along with myricetin
7.5 Flavanols in cooperation with standard cancer therapeutics
7.6 Combining conventional compounds with anthocyanins
8. Standard Drugs in Cooperation with Natural Non-Flavonoid Histone Deacetylase Inhibitors for Stunning Therapy Against Belligerent Malignancies
8.1 Combinatorial therapeutic approach involving organosulfurs
8.2 Stilbenes as adjuvant therapeutics with conventional antineoplastic agents
8.2.1 Resveratrol-conventional drug combination
8.2.2 Piceatannol together with certain conventional drugs
8.3 Conventional drugs in union with short chain fatty acids
8.4 Coumarins as adjuvants for standard antineoplastic agents
9. Enhancing Bioactivity and Bioavailability of Natural Histone Deacetylase Inhibitors Through Innovative Nanotechnological Approach
9.1 Nanoparticles containing single natural HDAC inhibitor
9.1.1 Nanoparticles loaded with Quercetin
9.1.2 Luteolin loaded nanovectors in cancer monotherapy
9.1.3 Resveratrol nanoparticles in singlet cancer therapy
9.1.4 Nanoparticles loaded with Chrysin for cancer treatment
9.1. 5 Nano-apigenin in cancer therapy
9.1.6 Anticancer monotherapy with rutin-nanoparticles
9.1.7 Piceatannol nanoparticles in singlet cancer therapy
9.1.8 Nano-encapsulated sulforaphane for therapy against cancer
9.2 Nanocombinatorial anticancer therapy with herbal HDACi
9.2.1. Quercetin in nano-combinational therapy
9.2.2 Luteolin-other molecules dual encapsulation
9.2.3 Resveratrol and standard drug co-encapsulation
9.3 Shortcomings of nanoparticles integrated with HDAC inhibitors
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Histone Deacetylases;Flavonoid;Anticancer monotherapy;Nanoformulations;Marine organisms;Combinatorial therapy;RKIP;Raf Kinase Inhibitor Protein;Nutrient Deprivation Autophagy Factor-1;ADR Cell;HDAC Inhibitor;Acute Myeloid Leukaemia Cells;Acute Myeloid Leukaemia;HDACi;ROS Generation;SIRT1;Hypoxia Inducible Factor Prolyl Hydroxylase;Classical HDACs;Acute Myeloid Leukaemia Patients;Isozyme Selective Inhibitors;Glioblastoma Stem Cells;Gemcitabine Resistant Pancreatic Cancer Cells;Acetylation Profile;Transcription Factor ZEB1;Main Short Chain Fatty Acid;Triple Negative Breast Cancer Cells;U937 Cells;Human Telomerase Reverse Transcriptase Promoter;Class IIa HDACs;JNK Cascade;Increase ROS Generation
1. Abridgement of Classical Histone Deacetylases, Their Inhibitors and Jeopardy of Synthetic Histone Deacetylase Inhibitors
Glimpse of HATs and HDACs
Family of Classical HDACs
Concise explanation of HDACi and their diverse groups
Disquietude of synthetic HDACi
2. Punctilious Overview of Stratification of Natural Histone Deacetylase Inhibitors and Their Different Provenances
2.1 Thorough Classification of Natural HDAC Inhibitors
2.2 Sources of Natural HDAC Inhibitors
2.2.1 Source of Cyclic tetrapeptide HDACi
2.2.2 Natural Hydroxamate HDACi source
2.2.3 Origin of Depsipeptide HDACi
2.2.4 Flavonoid HDACi and Their Natural Sources
2.2.5 Important sources of isothiocyanate group of HDACi
2.2.6 Main Sources of Organosulfur HDACi
2.2.7 Original Sources of Short Chain Fatty acid HDACi
2.2.8. Stilbenes and Their premier sources
2.2.9 Core sources of polyketide
2.2.10 Best sources of HDACi belonging to Bromo-tyrosine derivatives
2.2.11 Natural Origin of Coumarin Derivatives, Prenylated Isoflavones and other HDACi
3. Natural Cyclic Tetrapeptide Histone Deacetylase Inhibitors and Their Optimistic Role in Anticancer Therapy
3.1 Anticancer effect of Chlamydocin
3.2 Promising anticancer property of Apicidin
4. Anticancer Potential of Natural Hydroxamates and Depsipeptides Against Different Disease Models
4.1 Hydroxamate HDACi and their antineoplastic effect
4.2 Anticancer Property of Natural Depsipeptide HDACi
5. Promising Therapeutic Benefits of Flavonoid Histone Deacetylase Inhibitors with Special Emphasis on Modulation of Central Molecular Mechanisms
5.1 Short Introduction to Plant Derived HDAC Inhibitors
5.2 Classification of Phenolic Compounds and Flavonoids
5.3 Extensive Compendium of Flavonoid HDAC Inhibitors
5.4 Antineoplastic Effect of Isoflavonoid HDAC Inhibitors
5.5 Flavanones in obstructing cancer progression
5.6. Antineoplastic property of flavonols
5.6.1 Anticancer potential of Quercetin
5.6.2 Antineoplastic activity of Kaempferol
5.6.3 Antineoplastic characteristics of flavonol Isorhamnetin
5.6.4 Myricetin and fisetin as anticancer flavonols
5.7 Anti-tumour activity of Flavones
5.7.1 Apigenin based anticancer therapy
5.7.2 Chrysin as propitious molecule for belligerent cancers
5.7.3 Sanguine antineoplastic effects of Luteolin
5.7.4 Rutin as anticancer flavone
5.8 Flavanols and their role in cancer therapy
5.9 Anticancer characteristics of chalcones
5.9.1 Ovalitenin A and its role in hampering cancer
5.9.2 Licochalcone A as anticancer chalcone
5.9.3 Panduratin A and its anticancer benefits
5.9.4 Cardamonin as promising antineoplastic natural chalcone
5.9.5 Lonchocarpin and glimpse of its anti-tumour potential
5.10. Anthocyanins as anticancer flavonoids
6. Non-Flavonoid Histone Deacetylase Inhibitors from Natural Sources and Their Stupendous Anticancer Properties
6.1 Promising anticancer effect of isothiocyanates
6.2 Prodigious cytotoxic effect of bromotyrosine HDAC inhibitors
6.3 Cytotoxic effects of organosulfur compounds
6.4 Anticancer characteristics of natural short chain fatty acids
6.5 Antiproliferative effects of stilbenes
6.5.1 Resveratrol as antiproliferative stilbene
6.5.2 Piceatannol in abrogating cancer advancement
6.6 Coumarins in anticancer therapy
7. Flavonoid Inhibitors of Histone Deacetylases in Concert with Conventional Chemotherapeutic Agents for Phenomenal Therapy Against Cancer
7.1 Flavones in association with standard agents
7.1.1 Chrysin in cooperation with standard chemotherapeutics
7.1.2 Luteolin-conventional drugs combination
7.1.3 Apigenin in collaboration with standard cancer therapeutics
7.1.4 Rutin in combinatorial therapy
7.2 Isoflavones and conventional drugs combination
7.2.1 Standard drugs in combination with genistein
7.2.2 Conventional drugs and daidzein association
7.3 Flavanones in doublet therapy with conventional therapeutic molecules
7.3.1 Naringenin augments anticancer effect of usual anticancer drugs
7.3.2 Naringin reinforces effect of conventional antineoplastic agents
7.3.3 Hesperidin and hesperetin in concert with customary therapeutics
7.4 Flavonols in combinational therapy
7.4.1. Isorhamnetin as co-therapheutic with endorsed therapeutics
7.4.2 Quercetin and standard chemotherapeutics in concert
7.4.3 Combining conventional drug molecules with kaempferol
7.4.4 Fisetin-conventional drug combination
7.4.5 Standard drug molecules along with myricetin
7.5 Flavanols in cooperation with standard cancer therapeutics
7.6 Combining conventional compounds with anthocyanins
8. Standard Drugs in Cooperation with Natural Non-Flavonoid Histone Deacetylase Inhibitors for Stunning Therapy Against Belligerent Malignancies
8.1 Combinatorial therapeutic approach involving organosulfurs
8.2 Stilbenes as adjuvant therapeutics with conventional antineoplastic agents
8.2.1 Resveratrol-conventional drug combination
8.2.2 Piceatannol together with certain conventional drugs
8.3 Conventional drugs in union with short chain fatty acids
8.4 Coumarins as adjuvants for standard antineoplastic agents
9. Enhancing Bioactivity and Bioavailability of Natural Histone Deacetylase Inhibitors Through Innovative Nanotechnological Approach
9.1 Nanoparticles containing single natural HDAC inhibitor
9.1.1 Nanoparticles loaded with Quercetin
9.1.2 Luteolin loaded nanovectors in cancer monotherapy
9.1.3 Resveratrol nanoparticles in singlet cancer therapy
9.1.4 Nanoparticles loaded with Chrysin for cancer treatment
9.1. 5 Nano-apigenin in cancer therapy
9.1.6 Anticancer monotherapy with rutin-nanoparticles
9.1.7 Piceatannol nanoparticles in singlet cancer therapy
9.1.8 Nano-encapsulated sulforaphane for therapy against cancer
9.2 Nanocombinatorial anticancer therapy with herbal HDACi
9.2.1. Quercetin in nano-combinational therapy
9.2.2 Luteolin-other molecules dual encapsulation
9.2.3 Resveratrol and standard drug co-encapsulation
9.3 Shortcomings of nanoparticles integrated with HDAC inhibitors
Glimpse of HATs and HDACs
Family of Classical HDACs
Concise explanation of HDACi and their diverse groups
Disquietude of synthetic HDACi
2. Punctilious Overview of Stratification of Natural Histone Deacetylase Inhibitors and Their Different Provenances
2.1 Thorough Classification of Natural HDAC Inhibitors
2.2 Sources of Natural HDAC Inhibitors
2.2.1 Source of Cyclic tetrapeptide HDACi
2.2.2 Natural Hydroxamate HDACi source
2.2.3 Origin of Depsipeptide HDACi
2.2.4 Flavonoid HDACi and Their Natural Sources
2.2.5 Important sources of isothiocyanate group of HDACi
2.2.6 Main Sources of Organosulfur HDACi
2.2.7 Original Sources of Short Chain Fatty acid HDACi
2.2.8. Stilbenes and Their premier sources
2.2.9 Core sources of polyketide
2.2.10 Best sources of HDACi belonging to Bromo-tyrosine derivatives
2.2.11 Natural Origin of Coumarin Derivatives, Prenylated Isoflavones and other HDACi
3. Natural Cyclic Tetrapeptide Histone Deacetylase Inhibitors and Their Optimistic Role in Anticancer Therapy
3.1 Anticancer effect of Chlamydocin
3.2 Promising anticancer property of Apicidin
4. Anticancer Potential of Natural Hydroxamates and Depsipeptides Against Different Disease Models
4.1 Hydroxamate HDACi and their antineoplastic effect
4.2 Anticancer Property of Natural Depsipeptide HDACi
5. Promising Therapeutic Benefits of Flavonoid Histone Deacetylase Inhibitors with Special Emphasis on Modulation of Central Molecular Mechanisms
5.1 Short Introduction to Plant Derived HDAC Inhibitors
5.2 Classification of Phenolic Compounds and Flavonoids
5.3 Extensive Compendium of Flavonoid HDAC Inhibitors
5.4 Antineoplastic Effect of Isoflavonoid HDAC Inhibitors
5.5 Flavanones in obstructing cancer progression
5.6. Antineoplastic property of flavonols
5.6.1 Anticancer potential of Quercetin
5.6.2 Antineoplastic activity of Kaempferol
5.6.3 Antineoplastic characteristics of flavonol Isorhamnetin
5.6.4 Myricetin and fisetin as anticancer flavonols
5.7 Anti-tumour activity of Flavones
5.7.1 Apigenin based anticancer therapy
5.7.2 Chrysin as propitious molecule for belligerent cancers
5.7.3 Sanguine antineoplastic effects of Luteolin
5.7.4 Rutin as anticancer flavone
5.8 Flavanols and their role in cancer therapy
5.9 Anticancer characteristics of chalcones
5.9.1 Ovalitenin A and its role in hampering cancer
5.9.2 Licochalcone A as anticancer chalcone
5.9.3 Panduratin A and its anticancer benefits
5.9.4 Cardamonin as promising antineoplastic natural chalcone
5.9.5 Lonchocarpin and glimpse of its anti-tumour potential
5.10. Anthocyanins as anticancer flavonoids
6. Non-Flavonoid Histone Deacetylase Inhibitors from Natural Sources and Their Stupendous Anticancer Properties
6.1 Promising anticancer effect of isothiocyanates
6.2 Prodigious cytotoxic effect of bromotyrosine HDAC inhibitors
6.3 Cytotoxic effects of organosulfur compounds
6.4 Anticancer characteristics of natural short chain fatty acids
6.5 Antiproliferative effects of stilbenes
6.5.1 Resveratrol as antiproliferative stilbene
6.5.2 Piceatannol in abrogating cancer advancement
6.6 Coumarins in anticancer therapy
7. Flavonoid Inhibitors of Histone Deacetylases in Concert with Conventional Chemotherapeutic Agents for Phenomenal Therapy Against Cancer
7.1 Flavones in association with standard agents
7.1.1 Chrysin in cooperation with standard chemotherapeutics
7.1.2 Luteolin-conventional drugs combination
7.1.3 Apigenin in collaboration with standard cancer therapeutics
7.1.4 Rutin in combinatorial therapy
7.2 Isoflavones and conventional drugs combination
7.2.1 Standard drugs in combination with genistein
7.2.2 Conventional drugs and daidzein association
7.3 Flavanones in doublet therapy with conventional therapeutic molecules
7.3.1 Naringenin augments anticancer effect of usual anticancer drugs
7.3.2 Naringin reinforces effect of conventional antineoplastic agents
7.3.3 Hesperidin and hesperetin in concert with customary therapeutics
7.4 Flavonols in combinational therapy
7.4.1. Isorhamnetin as co-therapheutic with endorsed therapeutics
7.4.2 Quercetin and standard chemotherapeutics in concert
7.4.3 Combining conventional drug molecules with kaempferol
7.4.4 Fisetin-conventional drug combination
7.4.5 Standard drug molecules along with myricetin
7.5 Flavanols in cooperation with standard cancer therapeutics
7.6 Combining conventional compounds with anthocyanins
8. Standard Drugs in Cooperation with Natural Non-Flavonoid Histone Deacetylase Inhibitors for Stunning Therapy Against Belligerent Malignancies
8.1 Combinatorial therapeutic approach involving organosulfurs
8.2 Stilbenes as adjuvant therapeutics with conventional antineoplastic agents
8.2.1 Resveratrol-conventional drug combination
8.2.2 Piceatannol together with certain conventional drugs
8.3 Conventional drugs in union with short chain fatty acids
8.4 Coumarins as adjuvants for standard antineoplastic agents
9. Enhancing Bioactivity and Bioavailability of Natural Histone Deacetylase Inhibitors Through Innovative Nanotechnological Approach
9.1 Nanoparticles containing single natural HDAC inhibitor
9.1.1 Nanoparticles loaded with Quercetin
9.1.2 Luteolin loaded nanovectors in cancer monotherapy
9.1.3 Resveratrol nanoparticles in singlet cancer therapy
9.1.4 Nanoparticles loaded with Chrysin for cancer treatment
9.1. 5 Nano-apigenin in cancer therapy
9.1.6 Anticancer monotherapy with rutin-nanoparticles
9.1.7 Piceatannol nanoparticles in singlet cancer therapy
9.1.8 Nano-encapsulated sulforaphane for therapy against cancer
9.2 Nanocombinatorial anticancer therapy with herbal HDACi
9.2.1. Quercetin in nano-combinational therapy
9.2.2 Luteolin-other molecules dual encapsulation
9.2.3 Resveratrol and standard drug co-encapsulation
9.3 Shortcomings of nanoparticles integrated with HDAC inhibitors
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Histone Deacetylases;Flavonoid;Anticancer monotherapy;Nanoformulations;Marine organisms;Combinatorial therapy;RKIP;Raf Kinase Inhibitor Protein;Nutrient Deprivation Autophagy Factor-1;ADR Cell;HDAC Inhibitor;Acute Myeloid Leukaemia Cells;Acute Myeloid Leukaemia;HDACi;ROS Generation;SIRT1;Hypoxia Inducible Factor Prolyl Hydroxylase;Classical HDACs;Acute Myeloid Leukaemia Patients;Isozyme Selective Inhibitors;Glioblastoma Stem Cells;Gemcitabine Resistant Pancreatic Cancer Cells;Acetylation Profile;Transcription Factor ZEB1;Main Short Chain Fatty Acid;Triple Negative Breast Cancer Cells;U937 Cells;Human Telomerase Reverse Transcriptase Promoter;Class IIa HDACs;JNK Cascade;Increase ROS Generation
